Clinical Trials Browser

Phase 3 × Hyperparathyroidism, Primary × Denosumab × Clear all

NCT03027557 2021-05-25

DENOCINA

Phase 3 Completed

46 enrolled 49 charts

Parathyroid Neoplasms, Hyperparathyroidism, Primary